Brensocatib faces ICER spotlight with strong case for clinical and economic value
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
non-Cystic Fibrosis
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.